The introduction of new biological drugs for the treatment of rheumatoid arthritis and spondyloarthritis has led to the creation of a number of registries in Europe and the United States. Most of them are sponsored by national rheumatology societies, and provide information that is useful in clinical practice concerning the clinical characteristics, efficacy, and safety of all licensed biological drugs. Their findings also help to improve our understanding of the quality of life and working ability of patients receiving biological drugs, and suggest methods for allocating resources. However, there are only a few registries for psoriatic arthritis, and efforts should be made to increase their number to obtain further reliable and useful data.
Psoriatic arthritis registries / P. Sarzi-Puttini, V. Varisco, M.C. Ditto, M. Benucci, F. Atzeni. - In: THE JOURNAL OF RHEUMATOLOGY. SUPPLEMENT. - ISSN 0380-0903. - 93(2015 Nov), pp. 30-32.
|Titolo:||Psoriatic arthritis registries|
|Parole Chiave:||Psoriatric arthritis; registries; biological drugs; adverse events|
|Settore Scientifico Disciplinare:||Settore MED/16 - Reumatologia|
|Data di pubblicazione:||nov-2015|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.3899/jrheum.150631|
|Appare nelle tipologie:||01 - Articolo su periodico|